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Abstract
Background: Recently, there has been mounting interest in scaling-up vector control against malaria in Africa. It
needs to be determined if indoor residual spraying (IRS with DDT) will provide significant marginal protection
against malaria over current best practice of long-lasting insecticidal nets (LLINs) and prompt treatment in a
controlled trial, given that DDT is currently the most persistent insecticide for IRS.
Methods: A 2 armed cluster-randomised controlled trial will be conducted to assess whether DDT IRS and LLINs
combined provide better protection against clinical malaria in children than LLINs alone in rural Gambia. Each
cluster will be a village, or a group of small adjacent villages; all clusters will receive LLINs and half will receive IRS
in addition. Study children, aged 6 months to 13 years, will be enrolled from all clusters and followed for clinical
malaria using passive case detection to estimate malaria incidence for 2 malaria transmission seasons in 2010 and
2011. This will be the primary endpoint. Exposure to malaria parasites will be assessed using light and exit traps
followed by detection of Anopheles gambiae species and sporozoite infection. Study children will be surveyed at
the end of each transmission season to estimate the prevalence of Plasmodium falciparum infection and the
prevalence of anaemia.
Discussion: Practical issues concerning intervention implementation, as well as the potential benefits and risks of
the study, are discussed.
Trial Registration: ISRCTN01738840 - Spraying And Nets Towards malaria Elimination (SANTE)
Background
Although progress is being made [1], malaria remains
one of the world’s greatest childhood killers [2], con-
sumes almost half of the clinical services in Africa
(http://www.rbm.who.int), and is a substantial obstacle to
social and economic development in the tropics [3,4].
We know from historical accounts that in the 1950s and
1960s malaria was controlled using indoor residual
spraying (IRS) with DDT for vector control in many
parts of the tropics [5]. DDT was highly effective in redu-
cing malaria infection, but was not used widely in Africa.
Today, Roll Back Malaria is mainly concerned with
reducing the burden of disease and is gathering pace. The
Global Fund to fight AIDS, Tuberculosis and Malaria
(http://www.theglobalfund.org) and the US President’s
Malaria Initiative (http://www.fightingmalaria.gov) are
major players in malaria control and strategies towards
elimination in Africa, supported by a myriad of smaller
players. The current recommended best practice for
malaria control includes the use of Artemisinin-based
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any medium, provided the original work is properly cited.combination therapies and LLINs. The protective efficacy
of LLINs (or insecticide treated nets, ITNs) is well known
[6] and they are the cornerstone of malaria control in
many African countries, including The Gambia.
Recently, there has been mounting interest in scaling-up
IRS, and DDT in particular, for malaria control in Africa
as IRS is a passive and a highly equitable intervention
[7,8]. In 2009, 32 countries in Africa recommended IRS
for malaria control and 13 of those were using DDT
(http://www.who.int/malaria/world_malaria_report_2010).
In The Gambia, the National Malaria Control Programme
(NMCP) implemented DDT IRS over the entire country
in 2009. Given this ground swell of support for DDT-
based IRS it is surprising there is still a dearth of informa-
tion about the effectiveness of DDT IRS in Africa; Kouz-
netsov’s statement in 1977 is still valid; [there is a] ‘lack of
evidence that [IRS] schemes... are contributing to the
improvement of population health in highly endemic
levels of Africa’ [5]. A recent Cochrane review highlighted
the paucity of high-quality trials to inform decision mak-
ing about the use of IRS for malaria control [9], but con-
sidered that IRS reduces malaria incidence in areas of
stable transmission.
In contrast there is much stronger evidence that ITNs,
and by implication LLINs, are protective with a Cochrane
Review concluding that in areas of stable malaria they
reduce the incidence of uncomplicated malaria in children
by 50% compared to no nets [6]. There is a small body of
literature suggesting that ITNs may be more protective
than IRS in areas of unstable transmission, but conclude
that more trials need to be carried out [9]. The only direct
comparison made between ITNs and IRS with DDT that
we are aware of is in China where both treatments were
used separately and had a similar efficacy [10]. Thus no
large-scale trials have been carried out to investigate the
use of LLINs and IRS together, in comparison with LLINs
alone.
Specifically it is key to determine if IRS with DDT will
provide marginal protection against malaria over current
best practice of LLINs and prompt treatment in a con-
trolled trial, given that DDT is currently the most persis-
tent insecticide for IRS [11]. Since LLINs represent
‘current best practice’,w ep r o p o s et om e a s u r et h em a r -
ginal impact of IRS with DDT on malaria in communities
using LLINs and having access to rapid treatment by
conducting a cluster randomised intervention trial in
rural villages in Upper River Region (URR), The Gambia,
a country where malaria has been declining [12,13]. Here
we describe the study design and the methodology used.
Study objectives
Clinical
￿ Primary objective: To assess whether IRS with
DDT plus LLINs provide added protection against
clinical malaria in children compared with LLINs
alone.
￿ Secondary objective: To assess whether IRS with
DDT plus LLINs provide added protection against
anaemia and/or parasite prevalence in children com-
pared with LLINs alone.
Entomological
￿ Primary objective: To assess whether IRS with
DDT plus LLINs reduces vector density inside
houses when compared with LLIN alone.
Methods/Design
Study area and participant eligibility
The study is situated in the far east of The Gambia, in
URR, extending approximately 240 to 320 km inland
from the mouth of the Gambia River on the Atlantic
coast, an area of open Sudan savanna. The climate con-
sists of a single rainy season from May to October fol-
lowed by a long dry season. This defines the highly
seasonal malaria transmission with most malaria episodes
experienced during or immedia t e l yf o l l o w i n gt h er a i n y
season. This region covers an area of 1995 km
2 and is
bisected by the river into the north and south banks. The
population of the region was 182,586 in 2003, the most
recent census, with the majority living in small rural vil-
lages in houses made with mud or cement walls and
thatched or metal roofs. The study’s field station is based
at Basse Santa Su town (UTM coordinates 13.3167N,
-14.2167W) which is the only sizeable urban area.
Villages or groups of neighbouring villages, will be
selected for the study that have > 110 children aged 6
months -13 years and that are ≥2 km from another study
village to reduce likelihood of movement of mosquitoes
from one cluster to the next. The study cohort of chil-
dren, aged 6 months - 13 years old in June in Year 1,
who are village residents, will be enumerated and an
average of 110/cluster will be selected randomly and
invited to participate in the clinical surveys and passive
case detection (PCD). In order for the results from this
study to be as generalizable as possible, no distinctions
will be made regarding gender, ethnic group, medical
condition or physical health. Children will be included
providing their carers/parents give witnessed informed
written consent and, in the case of older children, assent
is provided. Assurance will also be sought from carers/
parents that they expect that the child will remain resi-
dent in their village during the transmission season and
will not be sent away for example for live stock herding
or schooling. Subjects and households are free to with-
draw from participating in the study at any time without
giving a reason. If consent is not provided then replace-
ment children will be randomly selected from those
remaining. In year 2, overage children will leave the study
and infants aged 6 to 18 months will be recruited; any
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son, will be replaced.
Study subjects will be enrolled in June 2010 in Year 1.
Enumeration, recruitment and survey of study subjects
and application of the interventions will take place over
2 months, before the start of the transmission season.
As is customary in The Gambia, sensitisation will start
by discussions with community elders and then the
whole study community in order to explain the nature
of the study and what will be required during the inter-
ventions and investigations. We will seek verbal consent
before IRS and verification of positioning of mosquito
traps, and written informed consent from the parents or
caregivers of all enrolled study children. During these
procedures it will be made clear that people will be able
to leave the study at any time.
Informed consent will be sought at the village level
after sensitization meetings attended by village commu-
nity leaders and health staff (community level informa-
tion sheet attached). The key attendees names and roles
will be documented for each village. Witnessed verbal
consent will be sought from each household head, or
representative, before IRS and before population, net
and house surveys.
A cohort of 8,000 children will be enrolled from all the
clusters to assess the impact of the intervention on
malaria. In approximately 50% of clusters, equally divided
between the two study arms, 6 rooms will be selected,
each with a single male sleeper, to monitor the impact of
the intervention on the density of malaria vectors and
their infection rate with malaria. These will be randomly
selected from households that have consented to join the
study, stratified by housing types in the cluster. Amongst
the selected households, potential rooms will be ran-
domly selected by numbering, the numbers being placed
in a hat and withdrawn blind. If the room owner does
not consent or withdraws from the study or moves away,
the process will be repeated.
Design
A cluster-randomized controlled study design will be
used, as IRS is a community-level intervention and the
village cluster as a suitable unit for randomization. All
households in all the clusters will be offered LLIN at no
cost to the recipients to enable all residents to benefit
from this intervention. The clusters will then be rando-
mized into two equal groups; all households in the vil-
lages in one group will be offered IRS and those in the
other group will not. It is not possible to conduct the IRS
in a blinded manner since a placebo would quickly be
identified by the community as non-protective. To assess
whether DDT IRS and LLINs combined provide better
protection against clinical malaria in children than LLINs
alone, 75- 125 children aged from 6 months to 13 years
old will be sampled according to cluster size enrolled
into a study cohort. These children will be followed dur-
ing the malaria transmission season in 2010 and 2011.
Clinical malaria will be recorded by study staff using
PCD in close collaboration with government health
workers both at the village and health facility levels. Para-
sites will be detected by a rapid diagnostic test (RDT,
Paracheck Pf, Orchid Biomedical Systems, Goa, India)
and treatment will follow government treatment
guidelines.
The study cohort will be surveyed for malaria indices
(parasite prevalence, anaemia and spleen rate) at the
end of both transmission seasons to generate data for
the secondary endpoints and also at baseline before the
year 1 transmission season. Baseline data will be used to
compare the 2 groups before the interventions and end
of season survey data will be used to attempt to define a
Plasmodium falciparum parasitaemia cut-off giving opti-
mum sensitivity and specificity for malaria cases in this
setting [14].
Exposure to malaria vector mosquitoes and parasites
indoors will be assessed using CDC light traps and win-
dow traps every 4 weeks from June to December and
every 8 weeks from January to May in at least 6 ran-
domly selected households in 16 village clusters in each
arm of the study. This will be followed by detection of
Anopheles gambiae species, parity status and sporozoite
infection. A schematic representation of the trial is
shown in Figure 1.
Randomisation
An equal number of clusters will be randomized to
receive IRS, in addition to the LLINs provided to all
enrolled households, and in these all households will be
treated. In cluster-randomised controlled trials it is parti-
cularly important to minimize imbalance for factors
known to be highly correlated with the disease outcome;
in this case age and access to health facilities and loca-
tion. At the village level we will stratify by presence of a
primary health care centre (PHC) and geographical loca-
tion by dividing the total area into four with two of equal
area on each bank of the river. Stratification for PHCs
will also ensure that the larger villages are evenly distrib-
uted in the experimental groups. In addition, balanced
randomization will be used to ensure that children of
similar ages are enrolled at the village level.
Stratified randomisation of villages to the study
groups, as outlined above, will reduce the likelihood of
chance imbalances between study arms but as only rela-
tively small number of units can be randomized in such
a cluster design, both groups cannot be assumed similar
for all factors. Baseline data on spleen rates, parasite
prevalence and anaemia will be collected on a represen-
tative sample of enrolled children in each village at the
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assess imbalances in malaria at village level.
Observer bias will be reduced where feasible. Blood
films will be read by microscopists blinded to the iden-
tity and intervention status of the subjects. Mosquito
collector bias will be reduced by using standard light
traps and exit traps, which do not rely on the ability of
the fieldworker to collect specimens. Trap catches will
be examined by a different person to the trap collector
and they will be blinded to the trap location. The
Prior to 
allocating 
interventions 
Prior to  
transmission  
season 
Beginning of   
transmission  
season 
(Continuous 
monitoring  
from beginning 
of transmission 
season to the 
end)
End of  
transmission  
season) 
In 2010 we will sensitize the communities and obtain village level consent prior to  mapping, 
and enumerating the 70 villages or village clusters. In 2011 we will check for new residents.
Distribution of LLIN at household level to achieve one LLIN per bed/ sleeping place in 2010  
and top-up in 2011.
Each year for two years we will spray DDT indoors in half the villages, allocated to 
intervention type by restricted randomisation 
Incidence of clinical malaria 
Prevalence of anaemia 
Prevalence of parasitaemia 
Density of . female An. gambiae 
Exposure of children to infectious An
gambiae
We will screen children for haemoglobin density and parasite prevalence in December 
2010 and 2011. 
Clinical morbidity will be monitored in study children by Passive Case Detection. Study 
nurses and fieldworkers will be posted to district health facilities and key village health posts
Study children will be checked monthly for residence and in September for use of LLIN.
Exposure to Anopheles gambiae mosquitoes will be measured by routine surveillance with
LT and ET made on one night every four weeks from June to December. 
MMX trap collections will be made outdoors to determine outdoor vector densities. 
We will enrol 9000 study children and screen them for haemoglobin density and parasite 
prevalence at the beginning of the transmission season in 2010.
Each year Village Health Workers will be provided with refresher training on malaria 
diagnosis and referral 
We will seek and obtain consent to trap mosquitoes using CDC light traps (LT), exit traps 
(ET) and MMX traps
Figure 1 Schematic of study design.
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will be closely monitored not only for quality but also to
document any bias between the villages.
Interventions
a) Indoor-residual spraying
In study clusters randomized to IRS, indoor residual
spraying will use a wettable powder of DDT (DDT- WP
75) manufactured to WHO specifications and supplied
by Hindustan Insecticide Ltd., New Delhi, India. Indoor
surfaces will receive DDT (2 g/m
2), in May/June, at the
start of the main malaria transmission season, in 2010
and 2011. DDT-WP 75, contains 500g of DDT per 670g
of product and is packaged in 670g/sachets for making
up to 10L with water. The sachets are clearly labelled
following WHOPES guidelines (WHO/CDS/WHOPES/
2003.7) and are delivered 25/heavy duty carton.
DDT will be stored to maintain efficacy and avoid
environmental contamination according to WHOPES
guidelines (WHO/CDS/WHOPES/2003.7) and in accor-
dance with the Gambian National Environmental
Agency’s regulations. Thus the study DDT will be stored
in a similar manner to DDT being used currently by the
NMCP. The cartons containing individual sachets will
b ec l e a r l ym a r k e dw i t ht h es t u d yn a m e( S A N T E )a n d
stored in a locked designated area in the Central Medi-
cal Stores until the week before the IRS campaign, each
year, when they will be moved to a locked designated
area at the Regional Store in Basse. While in the Central
and Regional Stores the DDT will be under the control
of the NMCP Study Investigators, who will supervise
the interventions. The product will be supplied with an
expiry date 2-years post-manufacture which will extend
beyond June 2011.
During the week before spraying, the sensitization
team will inform villages that their village has been
selected for IRS, the purpose of spraying, what is
required of householders and the excepted IRS date. On
the day of IRS, trained spray personnel will inform
householders of the spraying schedule and repeat the
p u r p o s eo fs p r a y i n ga n dw h a ti sr e q u i r e do fh o u s e -
holders. They will then allow the household time to pre-
pare and vacate the house. Occupants must leave houses
before spraying and any rooms occupied by sick people
who cannot be moved will not be sprayed. The house-
holder should remove all household items, including
water, food, cooking utensils and toys from the house.
When possible furniture should be moved outside; if
this is not possible, it should be moved to the middle of
the room to allow easy access for spraying walls and
covered. All wall hangings should be removed. When
water-jars cannot be removed they should be covered.
Pets and domestic animals should be tethered away
from the house. Rooms will not be sprayed if people or
animals are present, if household items are not correctly
removed or positioned or if the walls are covered with
gloss paint. Thatch ceilings also will be sprayed but not
tin or hardboard ones. Data will be collected on interior
wall surfaces at baseline. Householders will be allowed
back into their houses after spraying and will be asked
to mop any excess solution from the floors and wash
the floors with water before they allow children back
into the house. They are requested not to wash, paint or
re-plaster sprayed walls at least until the end of the
malaria transmission season.
b) Long-lasting insecticidal mosquito nets
LLINs distributed during this project will be Olyset
Nets, Sumitomo Chemicals. These meet WHO specifica-
tions (http://www.who.int/whopes/Long_lasting_insecti-
cidal_nets_Aug09.pdf) with permethrin at 2% w/w
incorporated into polyethylene fibres giving adequate
release of permethrin for up to five years. Recipients will
be offered a choice between the “large” conical (1250 cm
circumference, 65 cm top, 250 cm high) and the
“family” rectangular (160 cm wide × 180 cm l × 150 cm
h) models. Olyset nets are supplied in individual sachets
labelled by the manufacturers and they will be distribu-
ted to recipients in pre-opened individual sachets in
May 2010, at the beginning of the main transmission
season.
Olyset LLIN will be stored at ambient temperature in
locked rooms in Banjul and Basse and will be under the
control of the NMCP Study Investigators. LLIN distri-
bution will conducted in collaboration with the Regional
Government bednet distributors at no cost to the recipi-
ents. In advance of distribution, the number of beds/
sleeping places and the number with LLIN in excellent
condition will be counted. Distribution will be at the
household level to the household head or representative
to achieve one LLIN per bed/sleeping place. Net use by
study children will be monitored during the middle of
the transmission season in 2010 and 2011. Government
Roll Back Malaria information, education and communi-
cation procedures will be followed to encourage correct
net use and maintenance.
Clinical data collection and patient treatments
Passive surveillance for malaria will be maintained
throughout both transmission seasons. Parents/guar-
dians will be encouraged to take their child to the health
centre or health post identified as being closest to their
home at any time their child becomes unwell. The Vil-
lage Health Workers (VHW) who run the health posts
will use RDTs in their diagnosis of malaria and treat
malaria in children who are enrolled into the study.
Nurses placed in strategic health facilities will also per-
form a RDT in children who present directly to them
who are enrolled into the study. Project field workers or
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week, to record children with malaria episodes.
The parents of any child treated for malaria at a clini-
cal survey or during the passive surveillance will be
asked to bring their child to the nearest health facility if
the child does not show improvement within 48 h.
When such study subjects report to a health facility gov-
ernment nurses will treat the child following Gambian
government guidelines and inform the study nurse sta-
tioned in that facility. The study nurse will inform the
study physician of the case within a minimum of delay.
If such study subjects report to the VHW, he/she will
advise them to report to the nearest health facility.
Referred study subjects will be compensated for trans-
port to the health facilities.
The end of transmission season survey in December
2011 will be the final study visit for all enrolled children
and also the final study visit to the villages. The final
survey will be similar to the baseline and end of the first
transmission season survey in the previous year.
During the course of the study participants are free to
receive medication from health personnel outside the
study team. During the clinical surveys, iron supplemen-
tation will be given to any enrolled child with anaemia
(Hb < 9 g/dL). Artemether-lumefantrine (Co-Artem)
will be given to any child with a temperature of ≥37.5°C
or a history of fever in the past 48 h, and P. falciparum
parasites detected by RDT in the absence of other
detectable cause of fever. The parent/carer of any child
we treat for malaria will be asked to bring their child to
their nearest health post or facility if the child does not
make a recovery within 48 hours. Children with severe
malaria will be referred to Basse Health Centre for
treatment.
During the passive surveillance for malaria, parents/
carers of study children will be encourage to take their
child to the nearest VHW or Health Facility if the child
is unwell. In both cases children with symptoms sugges-
tive of malaria will be tested for the presence of para-
sites using RDTs. Treatment for other conditions will be
carried out in accordance with national guidelines and/
or referral to Government health facilities.
Entomological collections
Exposure to mosquitoes will be measured by surveil-
lance with light traps and house exit rates estimated
using window traps from June to November each year.
To obtain the primary entomological endpoint light
traps will be used. They are routinely used in The Gam-
bia and are unaffected by the presence of treated nets
[15]. A CDC miniature light trap will be positioned
close to one sleeper protected with a LLIN. Two esti-
mates of EIR and the number of sporozoite infective
bites/child/season will be calculated: one based on light
traps collections and one from exit traps. Parity will also
be assessed in female mosquitoes.
Clinical evaluations
The main morbidity outcome will be incidence of clini-
cal disease assessed by PCD; data from this will provide
the primary endpoint of the study. PCD is considered to
generate information of more direct relevance to public
health than active case detection and is thus more suita-
ble for evaluating population level malaria interventions
[16]. Mild malaria and parasitaemia is common in all
children in this area of highly seasonal malaria [17,18]
and we will enrol children aged 6 months - 13 years.
We previously developed a system in Gambian villages
where a trained MRC nurse provided diagnostic support
to the established VHW in the study villages [19]. Fol-
lowing this experience, in this study the nurses will pro-
vide training and ongoing support to the VHW for
diagnosis of malaria in consulting study children who
report with a history of fever in the last two days using
RDT and treatment of malaria. Study nurses at the
health facilities will document episodes of malaria in
study children who present directly to them on the Case
Report Form (CRF). At the health facilities malaria diag-
nosis will also rely on the use of RDT but, in addition,
thick blood films will be made for later staining with
Giemsa and microscopy to estimate parasite density in
this subset of cases. To facilitate documentation of all
clinical events (i.e. clinical consultations by study chil-
dren), all enrolled children will be issued with enumer-
ated photo identity cards; the study number and village
will be recorded for all clinical events on the CRF. The
project field workers or nurses that visit each VHW will
complete the CRF for all study subjects that consult
with the VHW.
All children present in their villages at the surveys will
be clinically examined for obvious symptoms and signs
of illness, temperature and spleen enlargement. A sam-
ple of all the study children, at least 50/village cluster
will be randomly selected stratified by age, and these as
well as those reporting fever in the last 48 hours and/or
with a temperature of ≥37.5°C will be finger pricked for
immediate measurement of anaemia and presence of
parasites by RDT. Anaemia will be assessed by measur-
ing haemoglobin concentration using a spectrophot-
ometer (HaemoCue
®) in the field.
The primary endpoint selected is the definition of
malaria used in The Gambia in research studies and in
the National Treatment Guidelines [18,20,21]. However,
a parasite cut-off level may increase specificity but the
gain in specificity cannot be known in advance with the
changing infection rates [12,13]. We thus also intend to
use the logistic regression method of Smith and collea-
gues [22] to examine the effect of parasite cut-off on the
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malaria. This method has recently been endorsed by a
WHO study group for use in studies defining malaria
vaccine efficacy [14].
Entomological evaluations
Exposure to mosquitoes will be measured by surveil-
lance with light traps and house exit rates estimated
using window traps to obtain the primary entomological
endpoint [23]. A CDC miniature light trap will be posi-
tioned close to one sleeper protected with a LLIN. Two
estimates of EIR and the number of sporozoite infective
bites/child/season will be calculated: 1 based on light
traps collections and 1 from window traps. Parity will be
recorded separately from both trap types.
Study procedures and evaluations
In advance of the spray campaign in year 1, spray opera-
tives and supervisors will be trained on the WHO meth-
ods for IRS with DDT for two weeks by the NMCP
vector control officer seconded to the project and an
internationally recognized IRS consultant. They will be
equipped with personnel protective clothing, including
boots, long-sleeved cotton overalls, hat, gloves, mask
and boots and trained in the maintenance and use of
these. Spray operatives will use spray pressurized canis-
ters made to WHO specifications WHO/VBC/89.970
(Hudson X-Pert
® Sprayer, 15L model 67422AD with
stainless steel nozzle (8002E), flat fan pattern, 80° angle,
flow rate 0.76L/min at 45psi pressure). They will be rig-
orously trained in the use of these and their mainte-
nance. A 2-day refresher training will be provided
before the spray campaign in year 2. Any remnant in
the sprayers at the end of daily spraying will be collected
following the “Progressive Rinse” method and recycled
to minimize waste (http://www.hdhudson.com/global-
public-health/newsletters/technical-information accessed
9th June 2011).
It is intended that both IRS and LLIN distribution will
be completed in May both years. In year 2 all house-
holds in the arm randomized to this intervention will
receive IRS as in year 1. LLIN distribution in year 2 will
be to residents who have relocated to study villages
since year 1.
Village health workers will be provided with refresher
training on diagnosis of malaria, the use of RDT and
study procedures in July 2010 by the study physician in
collaboration with study nurses and the community
health nurses. The methods used will be informed by
ongoing studies in The Gambia on the introduction of
RDT at all levels of health service. Refresher training
will be provided in 2011 before the transmission season.
Movement of children will be assessed at monthly
intervals on brief questionnaires to estimate the time at
risk and bednet usage will be assessed during these
house visits in August each year.
Thick blood films will be stained with Giemsa and
examined under 1000-fold magnification by trained,
experienced microscopists. Parasite counts will be
recorded per high power field and 100 fields will be
counted before a slide is declared negative. Parasite den-
sity will be estimated assuming that one parasite per
high power field equals 500 parasites/μl [24]. Two slides
will be prepared from each subject and read separately
by two experienced microscopists; discrepancies will be
resolved by a third reader.
Mosquitoes will be identified by microscopy and the
numbers of An gambiae s.l. and other species recorded.
T h ep r e s e n c eo fs p o r o z o i t e si nAn gambiae s.l. will be
identified using an enzyme-linked immunosorbent assay
[25] and An. gambiae s.l. females will be typed to the
species by PCR [26].
Safety considerations
There are no apparent risks to the safety of individuals
or communities in this study. Permethrin-treated long
lasting nets and DDT IRS has been fully evaluated by
the WHO Pesticide Evaluation Scheme and approved
for vector control (http://www.who.int/whopes/en/), and
the products will be used in compliance with their
recommended use and guidelines.
All children enrolled in the trial will have access to
malaria diagnosis and treatment according to Gambian
National Treatment Guidelines and all visits to the
VHW or health facilities will be documented on the
CRF.
In the case that a participant develops a serious
adverse event (SAE) during the course of the study this
w i l lb ec a p t u r e do nt h eC R Ff o rP C Di fi ti sa s s o c i a t e d
with a confirmed or suspected malaria episode. When a
study child consults with the VHW with a severe illness
that is not malaria, this will be captured in the VHW
daily log. The CRF for PCD or the details from the
VHW daily log will be submitted to the study physician
by the nurse or fieldworker responsible for the village-
cluster on a weekly basis. If it is a serious adverse event
(SAE) the study physician will record and manage the
SAE in accordance with Good Clinical Practice (GCP).
The study physician will check all CRF regularly, at
least once a week, and will inform the IDMC of the
numbers of malaria attacks and SAE by village as
required by the ID. Suspicion of potential harm to parti-
cipants or the environment caused by the interventions
may lead to discontinuation of the study. Excessive clus-
tering of SAE by village(s) will be reported to the study’s
Data Monitoring and Ethics Committee.
If an individual wants to terminate his/her participa-
tion, no further follow-up will be performed. In the case
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replaced in year 2 of the study (June 2011). There will
be no replacement during the surveillance period either
year. If a household withdraws consent, no further fol-
low-up will be made and there will be no replacement.
If a village opts out of the study before July in either
year replacement by a neighbouring village will be
considered.
Study endpoints
a) Clinical
Primary: Incidence of clinical episodes of malaria pre-
senting at health facilities defined as a child with an
axillary temperature of ≥37.5°C or a history of fever in
the past 48 h, together with the presence of P. falci-
parum parasites of any density detected by microscopy
and/or RDT in the absence of other detectable cause of
fever.
Secondary: (i) mean haemoglobin concentration in
children in the two study arms measured in the end of
the transmission season survey, (ii) parasite prevalence
in children in the two study arms measured at the end
of the transmission season.
In addition we will also calculate the incidence of
malaria defined by history of fever or temperature of
≥37.5°C and a P. falciparum parasitaemia cut-off to give
optimum sensitivity and specificity in this setting, and
number of children with enlarged spleens at the end of
the transmission season.
b) Entomological
Transmission parameters in the two arms of the study
will be estimated from measurements made throughout
the transmission season.
Primary: The mean number of female An. gambiae s.
l./light trap/night inside sleeping rooms.
Secondary: The entomological inoculation rate (EIR)
in each study group will be estimated as the mean num-
ber of sporozoite infective bites/child/season)
Tertiary: (i) The proportion of mosquitoes exiting
houses (since DDT has repellent properties), (ii) the
relative abundance of different members of the An. gam-
biae complex in light trap & exit traps collected in each
arm of the trial, (iii) the relative abundance of An. gam-
biae s.l. collected outdoors (iv) the parity of An. gam-
biae, to measure mean population longevity.
Sample Size Rationale
a) Clinical
Both LLINs and IRS alone reduce malaria morbidity by
approximately 50% [5,6]. The combined impact of these
two interventions is unknown. If the effects were simply
additive a mean reduction of 75% could be anticipated
for the combination, but the effects may be synergistic
(e.g. by having a mass killing effect) or antagonistic (e.g.
the repellency of DDT reducing Anopheline house entry
and contact with LLINs). To cover these possibilities we
expect that LLINs will reduce incidence by 50%, with
LLINs and IRS combined reducing the residual inci-
dence by 30-60% (i.e. 50% vs 65-80% fewer clinical cases
of malaria). A study of 3-60 month old children during
the end of the rainy season (Sept-Dec) in the URR in
2007 found a seasonal incidence of 0.79 (95% CI: 0.58-
1.08) cases/child-years by PCD (Bojang pers. comm.);
ITN prevalence was 50%. We estimate conservatively
that increasing LLIN provision to > 80% and inclusion
of older children will reduce incidence rates by about
60-80%, so incidence rates of 0.30 (LLINs) to 0.15 cases/
child-years (LLINs & IRS) have been included in the
sample size estimations. The study will also record PCD
over two high transmission seasons, not 1 as in the
Bojang study, further enhancing our ability to detect dif-
ferences between study arms. Estimations for k, the cor-
rected coefficient of variation to adjust for between
cluster variation (based on within and between cluster
variation) [27], from a cluster trial conducted in the
Central River Region of The Gambia in 2006/7 (K.
Bojang personal communication) varied from 0.31-0.43
and has been used to explore sample sizes (Figure 2).
T w oo ft h e5d i s t r i c t si nU R Rh a v e7 0v i l l a g e ss u i t a b l e
for the trial with over 100 children aged 6 months-14
years (predicted from the 2003 National Census) and
could accommodate an average cluster size of 110 chil-
dren (range 75-125). We plan to follow these children
for 22 weeks covering the peak malaria incidence season
each year, which, allowing for a 20% drop out rate over
the 2 years, yields 74.4 child-years per cluster. The
graphs below indicate a sample size of 5-39 clusters per
arm (Figure 2). Since estimates for incidence and drop-
out rate are conservative and the value of k may also be
reduced by the stratified design, we will recruit 35 clus-
ters in each arm of the trial.
Data from the same cluster trial quoted above was used
to explore sample size considerations for the parasitologi-
cal and anaemia, endpoints. Considering parasitaemia as
a proportion and haemoglobin as a concentration with
35 clusters of 110 children each suggested that sampling
half the child cohort would have 80% power to detect a
30% reduction in parasitaemia and a 0.5 mg/mL reduc-
tion in haemoglobin at 95% confidence.
b) Entomological
Previous studies with experimental huts indicated that
DDT IRS deterred 60-70% of mosquitoes from entering
houses [28]. LLINs were not associated with a deterrent
effect in Gambian houses [15]. Based on a study using
light traps in an adjacent study area in 2005, we expect
that the mean number of female An. gambiae s.l. per trap
will be 4.8 (with a coefficient of variation, k = 0.44). In
order to demonstrate a 60% reduction in hungry indoor
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IRS, with 90% power and at the 5% level of significance,
we would require 8 houses in each cluster and 12 clusters
in each arm of the trial over 2 years [27]. Since the num-
ber of mosquitoes rise and fall during the rainy season
we propose to sample from each house 6 times each year.
To allow for loss to follow-up due to people moving
house during the study period we propose to include at
least 8 houses in each cluster and 15 clusters in each
study arm for 2 years.
Data handling and record keeping
The demographic data will be recorded by fieldworkers
and the clinical data by study nurses on standardised
data forms. Each participant will have a unique identifi-
cation (ID) number. All data recorded on individuals
will be made by recording the anonymous ID.
Data forms will be scanned to produce electronic
copies and into the data set using Snap Survey (Version
10, Snap Survey Ltd., Haymarket, London, UK) software
and verified against electronic copies of the original
forms by data entry clerks to produce 2 independently
verified versions. These will be combined and errors
corrected to produce a single dataset. This will be sub-
mitted to consistency checking by generic and study
specific algorithms designed to identify sources of error.
When inconsistencies are found, these will be checked
against the original forms and subsequently amended in
the dataset. Errors will be corrected when possible, with
checking in the field when necessary and possible, to
produce final datasets.
All forms with subject names and/or clinical data will be
kept in a locked cabinet, when not in use, and the key
kept by the study coordinator or delegate. These datasets
will be, password protected. Data will be stored for at least
10 years. The clinical data will be kept separately from
that containing personal information. All forms and data-
sets, apart from those for enumeration, will identify sub-
jects by their subject specific ID and names will not be
collected or entered. After the collection and verification
in Snap Survey data will be moved to MRC’sS Q Ls e r v e r
2008 SWIFT. These datasets will be, password protected
and only accessed by senior study staff and the study Data
Manager. Data will be stored for at least 10 years.
The Principal Investigator (PI) will maintain appropri-
ate medical and research records for this study in com-
pliance with GCP and regulatory and institutional
requirements. Authorised representatives of the sponsor,
the ethics committee(s) or regulatory bodies may inspect
all documents and records required to be maintained by
t h ei n v e s t i g a t o r .T h eP Io rd e s i g n e ew i l le n s u r et h e
access to facilities and the records.
Figure 2 Sample size estimations at varying effect, incidence and coefficient of variation (CV).
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deviation from the approved protocol on the CRF,
where appropriate, and record and explain any deviation
in a file note that will be maintained as an essential
document. Deviations from the protocol, GCP or study
specific requirements that might have an impact on the
conduct of the study or the safety of participants will be
reported within 15 working days to the sponsor and
relevant Ethics Committee, as appropriate. Any other
protocol deviation will be reported to the local EC
together with the annual report.
Analytical plan
Outcome 1 - malaria morbidity
The primary endpoint is a comparison of the incidence
of clinical episodes of malaria in children in the 2 inter-
vention groups, measured by PCD. After a case of
malaria is treated, time of observation will be censored
f o r3w e e k sa n df u r t h e ra t t a cks of malaria during this
period are not considered. History of travel away from
the village for prolonged periods will be captured by
monthly surveys and time at risk will be censored for
such periods. In addition, malaria cases in children who
resided outside their study village for more than half the
elapsed study period at the time of illness will be cen-
sored. An initial unadjusted analysis will be based on
comparisons of the incidence rates between the 2
groups. Incidence rates will be calculated for each clus-
ter and the ratio of their un-weighted means will give
an estimate of the intervention effects. Confidence inter-
vals for the intervention effect will be obtained using
the approximations given by Bennett [29] and tested
using a bootstrapped [30] confidence interval. The inci-
dence rates for each cluster will also be used to perform
a hypothesis test based analysis between the 2 groups
using a 2 sample unpaired t-test. It is likely that the
r a t e sw i l lb eh i g h l ys k e w e da n di fn e c e s s a r yt h er a t e s
will be transformed. Using the incidence rates as a
response, linear regression can be used to adjust for
cluster level covariate effects. If the assumptions of nor-
mality and constant variance cannot be met, a non-para-
metric test (Mann-Whitney) will be used to compare the
2g r o u p s .T h ec l u s t e rr a n d o m ised trial will result in a
multi-level model with individuals within village. Indivi-
dual level covariates will be modelled using random
effects Poisson regression which will be fitted using
GLLAMM, a Stata program to fit generalized linear
latent and mixed models GLLAMM [31], to allow for
the clustering effect of village, compound and the effect
of repeated episodes in the same child. Year will be
included as a fixed effect which will allow any interac-
tion with the intervention to be quantified. Other poten-
tial confounders such as house architecture, bednet use
and recent antimalarial treatment will also be adjusted
for in the analysis. Should the data, be zero-inflated or
under/over dispersed modifications to the underlying
distributional assumptions will be examined. The time
to first infection will be examined using a survival analy-
sis approach. Initial unadjusted analysis will use Kaplan
Meier curves to compare the probability of subjects in
the two arms becoming infected as the malaria season
progresses. A Cox regression frailty model will be used
to adjust for covariates, allowing for the clustering. The
location of the infected subjects will be known to the
household level and this information will be used to
examine the spatial distribution of infection over time.
Within the larger villages formal methods such as k-
means fuzzy clustering [32] will be used to quantify
clusters of infection.
Outcome 2 - malaria transmission
Differences in malaria transmission experienced in the 2
groups will be made by comparing the mean number of
mosquitoes caught indoors in houses between the inter-
vention groups. Generalised estimating equations will be
used to estimate differences in numbers of indoor-rest-
ing mosquitoes, adjusting for repeated measures within
clusters and possible covariates.
Secondary endpoints
For the secondary clinical endpoints we will compare: (i)
mean haemoglobin concentration in children at the end
of the transmission season, (ii) incidence of malaria
defined by history of fever or temperature of ≥37.5°C
and a P. falciparum parasitaemia cut-off defined to give
optimum sensitivity and specificity in this setting, (iii)
parasite prevalence in children at the end of the trans-
mission season, (iv) number of children with enlarged
spleens at the end of the transmission season. In gen-
eral, all quantitative outcomes will be compared using
appropriate summary statistics, such as mean differences
or risk ratios. Hypothesis testing will be based on a two
sample unpaired t-test, adjusting for possible co-variates.
If the data do not satisfy normality and constant var-
iance assumptions, an appropriate non-parametric test
will be used. Both linear regression (for continuous vari-
ables such as haemoglobin levels) and logistic regression
(for dichotomous variables such as presence or absence
of parasitaemia) will be used to quantify the group dif-
ferences allowing for individual level covariates (such as
age, house design, bed net use) using random effects to
allow for clustering.
Timetable of activities
The timetable of activities is shown in Table 1.
Ethical approval
This study is conducted in accordance with the princi-
ples set forth in the ICH Harmonised Tripartite Guide-
line for GCP and the Declaration of Helsinki in its
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to the participants. It was approved by the Gambian
Government/MRC Laboratories Joint Ethics Committee
first approved on the 12th August 2008 (ref: L2009.15,
L2010.19; SCC1128) and the London School of Hygiene
and Tropical Medicine Ethics Committee approved on
the 16th September 2009 (ref: 5592).
Discussion
As enthusiasm for malaria control in Africa gathers pace,
there is an urgent need to evaluate the effectiveness of
multiple interventions. This study evaluates the efficacy
of the 2 most common vector control tools used for
malaria control: IRS and LLINs. This study sets out to
examine whether there is an additional benefit of using
IRS in combination with LLINs compared to current best
practise, the use of LLINs alone. It is designed to measure
whether the double intervention will provide greater
protection against malaria incidence by substantially
reducing transmission.
The main morbidity outcome will be incidence of clin-
ical disease assessed using PCD. PCD is considered to
Table 1 Timetable of activities
Activity J F M A M J J A S O N D
2010
Senior staff recruitment X
Ethical approval X X
Order and shipment of equipment X X X
Field staff recruitment & training X X
Training of sprayteams, planning IRS X
Sensitisation of study population X X X
Enumeration & house selection for entomology X
House spraying & LLIN distribution X X
Selection subjects, PCD, & travel monitoring X X X X X X
Entomological surveys X X X X X X
Clinical & bednet surveys X X X
Data programming and entry X X X X X X X X
2011
Steering Group Meeting in The Gambia X
ELISA and PCR assays X X X
Data entry cleaning & report writing X X X X
Sensitisation of study population X X
House selection for entomology X X
House spraying & LLIN distribution X X
Replace subjects, PCD & travel monitoring X X X X X X
Entomological surveys X X X X X X
Cost data collection XX
Clinical & bednet surveys XX
Data analysis XX
Data entry XXXXXXX
2012
Data entry, cleaning & analysis X X X X
Steering Group Meeting in the UK X
Report findings to study communities X
Data analysis & report writing X X X X X
Cost effectiveness analysis X
Final report to the Steering Committee X
Report findings to Gambian Government X
Scientific paper writing X X X X X X X X X
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health than active case detection and is thus more suita-
ble for evaluating population level malaria interventions
[16]. It is especially relevant as many African countries,
the Gambia included, have launched policies that
malaria should be eliminated as a public health problem.
All the clinical outcomes will be measured in a cohort
of children aged 6 months to 13 years of age following
the age pattern of disease and infection in this area. In
areas of high malaria transmission the main burden of
paediatric malaria is borne by children under 5 years
old, but this pattern shifts to include older children and
adolescents in areas with lower levels of transmission
for example Ndiop in Senegal and the Farafenni area of
The Gambia [17,33]. This trend is increasing as malaria
decreases for example a recent study in the Gambia and
Guinea Bissau, which included a site in the URR, found
parasite prevalence highest in the 11 - 15 years olds
[34]. The lower limit of 6 months has been selected in
the current study for cultural and clinical reasons and
the upper limit corresponds to the age when most chil-
dren move to middle schools (Upper Basic) which are
often further away from their village. In addition to
quantifying malaria incidence and parasite prevalence
we will measure anaemia in both the community sur-
veys and at the time of clinical attacks and all subjects
with Hb < 8 gm/dL will receive treatment. In addition
to the clinical benefit, malaria is a major risk for anae-
mia in these populations [35], as other causes, such as
hookworm infection are infrequent, and documented
changes in anaemia will complement the main
outcomes.
There are no apparent risks to the safety of individuals
or communities in the use of these interventions. Perme-
thrin-treated long lasting nets and DDT-WP have been
fully evaluated by the WHO Pesticide Evaluation Scheme
and approved for vector control [11]. The biggest hazard
associated with the trial is the leakage of insecticide, par-
ticularly DDT, into the external environment. National
guidelines for insecticide transport, storage and all opera-
tional procedures will be strictly followed to ensure that
this remains unlikely. However, in The Gambia about 5%
of rural traditional houses are destroyed each year during
the rains [36], suggesting that some DDT may become
disseminated into the environment.
LLIN are similarly beneficial at the individual level,
and at the community level where high coverage is
attained. However, in The Gambia no community pro-
tection has been found with ITNs [37-39] as it has in
other parts of Africa [40,41]. Study children will benefit
from a health check at the surveys and at both the vil-
lage and health facility levels clinical services will be
supported by training and the presence of study nurses
in addition to government staff.
It is also important that the correct normal practice of
parents/carers in the case of their child becoming sick is
not altered in a detrimental fashion by their child being
enrolled in the study. For example a parent/carer may
delay taking a child to the nearest health facility/post if
they think that a study nurse is visiting their village the
next day. Both the provision of fares when a children
reports sick at a health facility and emphasis of the vital
role of parent/carers during enrolment and the conduct
of the study will help to mitigate against this.
T h e r ei sc u r r e n t l yar u s hf o rD D TI R Si nm a n yA f r i -
can countries, yet we lack the evidence of the protective
efficacy of this intervention against clinical malaria. To
date, most trials have been non-randomised and, often
non-controlled, making it difficult to evaluate protective
efficacy [42]. The proposed trial is urgently needed to
inform policy makers of any additional benefit of using
IRS with DDT together with current best practice
(LLINs). Indeed this is considered a priority area of
research by Roll Back Malaria (http://www.rollbackma-
laria.org). The trial will benefit our collaborators at the
NMCP in The Gambia by providing capacity building:
developing management systems, resistance monitoring
strategies and providing training on IRS according to
t h ep r i n c i p l e sl a i dd o w nb yW H O[ 4 3 ] .T h i si sp a r t i c u -
larly timely since a major IRS programme with DDT is
underway. The findings from this study will provide
valuable information to inform policy decisions, both in
this region and elsewhere, regarding how best to use
scarce health care resources to control malaria most
effectively.
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